Literature DB >> 23750540

Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.

Naohiro Watanabe1, Yoshio Nakahara, Hiroyuki Taniguchi, Tomoki Kimura, Yasuhiro Kondoh, Kensuke Kataoka, Koji Sakamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23750540     DOI： 10.3109/0284186X.2013.802838

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  7 in total

Review 1.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Authors:  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim
Journal:  Mol Clin Oncol       Date:  2017-08-11

3.  Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

Authors:  Yuzo Yamamoto; Isamu Okamoto; Kohei Otsubo; Eiji Iwama; Naoki Hamada; Taishi Harada; Koichi Takayama; Yoichi Nakanishi
Journal:  Invest New Drugs       Date:  2015-09-04       Impact factor: 3.850

4.  Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy.

Authors:  Vinayak V Maka; Uma Maheshwari Krishnaswamy; N Anil Kumar; Rohith Chitrapur; Nalini Kilara
Journal:  Oxf Med Case Reports       Date:  2014-04-08

5.  Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib.

Authors:  Nobuhiro Kanaji; Akira Tadokoro; Naoki Watanabe; Takuya Inoue; Tomoya Ishii; Hiroaki Dobashi; Shuji Bandoh
Journal:  Am J Case Rep       Date:  2014-11-03

6.  A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.

Authors:  Hiroaki Tachi; Kengo Nishino; Taisuke Nakaizumi; Kenya Kuramoto; Kei Shimizu; Yusuke Yamamoto; Keisuke Kobayashi; Hideo Ichimura; Akiko Sakata; Takeshi Nawa
Journal:  Thorac Cancer       Date:  2020-05-20       Impact factor: 3.500

7.  Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

Authors:  Ken Koshikawa; Jiro Terada; Mitsuhiro Abe; Shunichiro Iwasawa; Masashi Sakayori; Keiichiro Yoshioka; Yasutaka Hirasawa; Hajime Kasai; Yohei Kawasaki; Kenji Tsushima; Koichiro Tatsumi
Journal:  Thorac Cancer       Date:  2020-04-01       Impact factor: 3.500
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.